Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1997-9-9
|
| pubmed:abstractText |
Twenty-one high-risk patients with primary stage II/III breast cancer were treated with high-dose chemotherapy comprising etoposide, ifosfamide, carboplatin and epirubicin (VIC-E). Tumor cells of epithelial origin were analyzed using the monoclonal antibodies CK2 (IgG1) and A45-B/B3 (IgG1) against cytokeratin (CK) components in bone marrow (BM) aspirates prior to chemotherapy, and in peripheral blood stem cell transplants (PBSCT). They were separated after the first (21/21 patients) and the second cycle (16/21 patients) of induction chemotherapy with VIP-E (etoposide, ifosfamide, cisplatin, epirubicin). Preliminary results showed CK positive tumor cells in 40% (14/35) of the analyzed transplants. In 7/12 (58.3%) patients, CK positive tumor cells were detectable in BM prior to treatment. Sixteen patients were separated after the 1st and 2nd cycle of VIP-E. PBSCT of 14/16 patients were assessable for presence of CK positive tumor cells. Our preliminary results demonstrate a lower tumor cell contamination of PBSCT separated after the 2nd cycle of induction therapy (14.3%) compared to contamination after the first induction therapy (64.3%). To date, 4/21 patients have experienced a relapse, and three of these patients had tumor cell positive transplants. Due to the small patient number only a trend towards a superior relapse-free survival in the patient group with CK negative transplants can be shown by Kaplan-Meier analysis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1223-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9208116-Adult,
pubmed-meshheading:9208116-Antibodies, Monoclonal,
pubmed-meshheading:9208116-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9208116-Bone Marrow Purging,
pubmed-meshheading:9208116-Bone Marrow Transplantation,
pubmed-meshheading:9208116-Breast Neoplasms,
pubmed-meshheading:9208116-Cell Separation,
pubmed-meshheading:9208116-Combined Modality Therapy,
pubmed-meshheading:9208116-Female,
pubmed-meshheading:9208116-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9208116-Humans,
pubmed-meshheading:9208116-Keratins,
pubmed-meshheading:9208116-Middle Aged,
pubmed-meshheading:9208116-Neoplasm Staging,
pubmed-meshheading:9208116-Risk Factors,
pubmed-meshheading:9208116-Time Factors,
pubmed-meshheading:9208116-Transplantation, Autologous
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
|
| pubmed:affiliation |
2 Medizinische Klinik, Zentralklinikum, Augsburg, Germany.
|
| pubmed:publicationType |
Journal Article
|